表紙
市場調查報告書

人體微生物群治療藥的全球市場預測 (2020∼2030年) :腸胃障礙、感染疾病、代謝疾病、皮膚疾病、其他疾病

Global Human Microbiome Therapeutics Market Forecast 2020-2030: Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders

出版商 Visiongain Ltd 商品編碼 927176
出版日期 內容資訊 英文 345 Pages
商品交期: 最快1-2個工作天內
價格
人體微生物群治療藥的全球市場預測 (2020∼2030年) :腸胃障礙、感染疾病、代謝疾病、皮膚疾病、其他疾病 Global Human Microbiome Therapeutics Market Forecast 2020-2030: Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders
出版日期: 2019年11月29日內容資訊: 英文 345 Pages
簡介

全球人體微生物群治療藥市場在預測期間的前半部分預計將以80.2%的CAGr成長。全球人體微生物群市場預測將在2025年達到16億美元的規模。

本報告提供本報告提供全球人體微生物群治療藥市場相關調查,市場概要與各市場區隔,各地區趨勢,及加入此市場的主要企業簡介等系統性資訊。

第1章 報告概要

第2章 人體微生物群的簡介

  • 醫藥品產業:簡單的簡介
  • 健康的人體微生物群 (人微生物叢)
    • 微生物和主人的相互作用
    • 人體微生物群的生態系統
  • 病的人體微生物群
    • 健康和疾病中微生物所扮演的角色(健康的人體微生物群)
    • 益生菌和益生元對腸內細菌叢的影響
  • 開發中的微生物計劃
  • 作為治療方法的微生物的障礙
  • 微生物的未滿足需求

第3章 全球人體微生物群病患的負擔

第4章 人體微生物群治療藥:市場區隔

  • 腸胃障礙
  • 感染疾病
  • 代謝及肝臟病變
  • 皮膚疾病

第5章 臨床試驗的階段

第6章 人體微生物群治療藥:市場定義

  • 全球人體微生物群治療藥:預測
  • 全球人體微生物群治療藥市場:市場概要
  • 全球人體微生物群治療藥市場
  • 全球人體微生物群治療藥市場:預測
  • 人體微生物群治療藥:市場佔有率的變化,各部門

第7章 全球人體微生物群治療藥市場:各部門的市場預測

    腸胃障礙次級市場預測
  • 感染疾病次級市場預測
  • 代謝疾病次級市場預測
  • 皮膚疾病次級市場預測
  • 其他的疾病 (心血管,CNS,癌症) 次級市場預測

第8章 全球人體微生物群治療藥市場潛在性

    腸胃障礙
  • 感染疾病
  • 代謝疾病
  • 皮膚疾病
  • 其他的疾病

第9章 主要國家市場

  • 各地區
  • 主要國家市場預測
  • 美國
  • EU5個國家
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 亞太地區
  • 日本
  • 其他 (RoW)

第10章 治療藥相關的交易:各年度

第11章 主要企業

  • 4D Pharma Plc.
  • Synthetic Biologics
  • Seres Therapeutics
  • Ferring Pharmaceuticals
  • AOBiome Therapeutics
  • Osel Inc.
  • Immuron Ltd
  • Ritter Pharmaceuticals, Inc.
  • Intrexon Corporation
  • Synlogic
  • C3J Therapeutics
  • Finch Therapeutics/Crestovo
  • MaaT Pharma
  • IGEN BIOTECH GROUP
  • MatriSys Biosystem
  • Second Genome
  • Microbiome Therapeutics LLC
  • Caelus Health
  • Enterome Bioscience
  • Vedanta Biosciences
  • Symberix
  • Quorum Innovations
  • Assembly Biosciences
  • Evelo Biosciences, Inc.
  • LOCUS BIOSCIENCES, INC.
  • ImmuneBiotech
  • LNC Therapeutics
  • BiomX
  • Symbiotix Biotherapies, Inc.
  • LEADING BIOSCIENCES INC.
  • Azitra
  • Rebiotix Inc.

第12章 腸胃障礙:主要產品

第13章 代謝障礙:主要產品

第14章 感染疾病:主要產品

第15章 皮膚疾病:主要產品

第16章 其他障礙:主要產品

第17章 定性分析

第18章 結論

附錄

目錄
Product Code: PHA0622

The global human microbiome therapeutics market is estimated to grow at a CAGR of 80.2% in the first half of the forecast period. The global human microbiome therapeutics market is estimated to reach $1.6bn in 2025.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 345-page report you will receive 150 tables and 78 figures - all unavailable elsewhere.

The 345-page report provides clear detailed insight into the global human microbiome therapeutics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Human Microbiome Therapeutics Market forecast from 2020-2030

Global Human Microbiome Therapeutics Market revenue forecast 2020-2030 by Sector:

  • Gastrointestinal Disorders
  • Infectious Diseases
  • Metabolic Diseases
  • Dermatological Conditions
  • Other Disorders

Global Human Microbiome Therapeutics Market revenue forecast 2020-2030 by Region:

  • U.S.
  • EU5: Germany, France, U.K., Italy, Spain
  • APAC: Japan, China, India, Australia, Korea
  • Rest of the World

The human microbiome market revenue forecast 2019-2029 for the US, EU5 and APAC markets are further broken down by sector.

This report discusses the top 20 companies in the human microbiome therapeutics market:

  • 4D Pharma
  • AOBiome Therapeutics
  • C3J Therapeutics
  • Caelus Health
  • Enterome Bioscience
  • Ferring Pharmaceuticals
  • Finch Therapeutics/Crestovo
  • IGEN BIOTECH GROUP
  • Immuron
  • Intrexon Corporation
  • MaaT Pharma
  • MatriSys Biosystem
  • Microbiome Therapeutics LLC
  • Osel
  • Ritter Pharmaceuticals
  • Second Genome
  • Seres Therapeutics
  • Synlogic
  • Synthetic Biologics
  • Vedanta Biosciences

This report discusses collaborations and acquisition, recent developments, drugs developments and key pipeline products

This report lists and discusses the main pipeline products in these main sectors: gastrointestinal disorders submarket, metabolic disorders submarket, infectious diseases submarket, dermatological disorders submarket and other disorders submarket.

Qualitative analysis of the human microbiome therapeutics market in the form of a SWOT Analysis.

Key Questions Answered by this Report:

  • How is the market for human microbiome therapeutics evolving?
  • What is driving and restraining the human microbiome therapeutics market dynamics?
  • What are the market shares of the submarkets for gastrointestinal disorders, infectious diseases, metabolic diseases, dermatological conditions, and other disorders from the overall human microbiome therapeutics market?
  • How will each of the submarket segments within the human microbiome therapeutics market grow over the forecast period and how much revenue will these submarkets account for in 2030?
  • How will the market shares for each of the submarkets within the human microbiome therapeutics market develop from 2020 to 2030?
  • Which submarkets will be the main driver of growth in the overall market from 2020 to 2030?
  • How will the regional market shares in the human microbiome therapeutics market change by 2030 and which geographical region will lead the market in 2030?

Visiongain's study is intended for anyone requiring commercial analyses for the global human microbiome therapeutics market. You find data, trends and predictions.

Buy our report today Global Human Microbiome Therapeutics Market Forecast 2020-2030: Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Global Human Microbiome Therapeutics: Market Overview
  • 1.2 Global Human Microbiome Therapeutics: Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who Is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. An Introduction to Human Microbiome

  • 2.1 The Pharmaceutical Industry: A Brief Introduction
  • 2.2 Human Microbiota in Health
    • 2.2.1 Microbiome-Host Interaction
    • 2.2.2 Human Microbiota Ecosystems
  • 2.3 Human Microbiota in Disease
    • 2.3.1 Role of Microbiota in Health and Disease (Human Microbiota in Health)
    • 2.3.2 Effects of Probiotics and Prebiotics on gut microbiota
  • 2.4 Microbiome Projects under development
  • 2.5 Hindrances for Microbiome as therapy
  • 2.6 Unmet needs of Microbiome

3. The Global Burden of Human Microbiome Diseases

4. Human Microbiome Therapeutics: Market Segmentation

  • 4.1 Gastrointestinal Disorders
    • 4.1.1 Classification of Gastrointestinal Disorders
    • 4.1.2 Role of Microbiota in Gastrointestinal Disorders
  • 4.2 Infectious Disorders
    • 4.2.1 Classification of Infectious Disease
    • 4.2.2 Role of Microbiota in Infectious Disease
  • 4.3 Metabolic & Liver Disorders
    • 4.3.1 Classification of Metabolic & Liver Disorder
    • 4.3.2 Role of Microbiota in Metabolic Disorders
  • 4.4 Dermatological Conditions
    • 4.4.1 Classification of Dermatological Conditions
    • 4.4.2 Role of Microbiota in Dermatological Conditions

5. Phases of Clinical Trials

6. Human Microbiome Therapeutics: Market Definition

  • 6.1 The Global Human Microbiome Therapeutics Market, 2020-2030
  • 6.2 The Global Human Microbiome Therapeutics Market: Market Overview
  • 6.3 The Global Human Microbiome Therapeutics In 2020
  • 6.4 The Global Human Microbiome Therapeutics Market Forecast 2020-2030
  • 6.5 Human Microbiome Therapies: Changing Market Shares by Sector 2020-2030

7. Global Human Microbiome Therapeutics Market by Sector: Market Forecast 2020-2030

  • 7.1 Gastrointestinal Disorders Submarket Forecast 2020-2030
  • 7.2 Infectious Diseases Submarket Forecast 2020-2030
  • 7.3 Metabolic Diseases Submarket Forecast 2020-2030
  • 7.4 Dermatological Conditions Submarket Forecast 2020-2030
  • 7.5 Other Disorders (Cardiovascular, CNS, Cancer) Submarket Forecast 2020-2030

8. Global Microbiome Therapeutics Market Potential

  • 8.1 Microbiome Therapeutics Market Potential for GI Disorders
  • 8.2 Microbiome Therapeutics Market Potential for Infectious Disorders
  • 8.3 Microbiome Therapeutics Market Potential for Metabolic Disorders
  • 8.4 Microbiome Therapeutics Market Potential for Dermatological Conditions
  • 8.5 Microbiome Therapeutics Market Potential for Other Disorders

9. Leading National Markets for Human Microbiome Therapies: Market Forecast 2020-2030

  • 9.1 The Human Microbiome Therapeutics Market by Region
    • 9.1.1 Global Distribution of Human Microbiome Therapeutics, 2021
  • 9.2 Leading National Markets: Forecast 2020-2030
    • 9.2.1 Changing Market Shares by Region, 2020-2030
  • 9.3 United States
    • 9.3.1 The United States Human Microbiome Therapeutics Market: Market Forecast 2020-2030
    • 9.3.2 The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
      • 9.3.2.1 The United States Human Microbiome Therapies: Changing Market Shares by Sector 2020-2030
  • 9.4 EU5
    • 9.4.1 EU5 Human Microbiome Therapeutics Market: Market Forecast 2020-2030
      • 9.4.1.1 EU5 Markets: Changing Market Shares by Country, 2020-2030
    • 9.4.2 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
      • 9.4.2.1 EU5 Human Microbiome Therapies: Changing Market Shares by Sector 2020-2030
  • 9.5 Germany
    • 9.5.1 German Human Microbiome Therapeutics Market: Market Forecast 2020-2030
    • 9.5.2 German Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
      • 9.5.2.1 German Human Microbiome Therapies: Changing Market Shares by Sector, 2020-2030
  • 9.6 France
    • 9.6.1 French Human Microbiome Therapeutics Market: Market Forecast 2020-2030
    • 9.6.2 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
      • 9.6.2.1 French Human Microbiome Therapies: Changing Market Shares by Sector, 2020-2030
  • 9.7 UK
    • 9.7.1 UK Human Microbiome Therapeutics Market: Market Forecast 2020-2030
    • 9.7.2 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
      • 9.7.2.1 UK Human Microbiome Therapies: Changing Market Shares by Sector, 2020-2030
  • 9.8 Italy
    • 9.8.1 Italian Human Microbiome Therapeutics Market: Market Forecast 2020-2030
    • 9.8.2 Italian Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
      • 9.8.2.1 Italian Human Microbiome Therapies: Changing Market Shares by Sector, 2020-2030
  • 9.9 Spain
    • 9.9.1 Spanish Human Microbiome Therapeutics Market: Market Forecast 2020-2030
    • 9.9.2 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
      • 9.9.2.1 Spanish Human Microbiome Therapies: Changing Market Shares by Sector, 2020-2030
  • 9.10 APAC
    • 9.10.1 APAC Human Microbiome Therapeutics Market: Market Forecast 2020-2030
      • 9.10.1.1 APAC Markets: Changing Market Shares by Country, 2020-2030
    • 9.10.2 APAC Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
      • 9.10.2.1 APAC Human Microbiome Therapies: Changing Market Shares by Sector 2020-2030
  • 9.11 Japan
    • 9.11.1 The Cost of Treatment in Japan
    • 9.11.2 Japanese Pharmaceutical Industry Regulatory Reform
    • 9.11.3 Japanese Human Microbiome Therapeutics Market Forecast 2020-2030
    • 9.11.4 Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
      • 9.11.4.1 Japan Human Microbiome Therapies: Changing Market Shares by Sector, 2020-2030
  • 9.12 Rest of the World
    • 9.12.1 Rest of the World Human Microbiome Therapeutics Market: Market Forecast 2020-2030

10. Deals in Human Health Therapeutics by Year

11. Leading Companies in the Human Microbiome Therapeutics Market, 2020-2030

  • 11.1 4D Pharma Plc.
    • 11.1.1 4D Pharma: Collaborations and Acquisitions
    • 11.1.2 4D Pharma: Microbiome Drugs Development Pipeline, 2019
    • 11.1.3 4D Pharma: Recent Developments
    • 11.1.4 4D Pharma: Key Pipeline Products
  • 11.2 Synthetic Biologics
    • 11.2.1 Synthetic Biologics: Collaborations and Agreement
    • 11.2.2 Synthetic Biologics: Drug Development Pipeline, 2019
    • 11.2.3 Synthetic Biologics: Recent Developments
    • 11.2.4 Synthetic Biologics Key Pipeline Products,2019
  • 11.3 Seres Therapeutics
    • 11.3.1 Seres Therapeutics: Collaborations and Agreement
    • 11.3.2 Seres Therapeutics: Drug Development Pipeline, 2019
    • 11.3.3 Seres Therapeutics: Key Pipeline Products
  • 11.4 Ferring Pharmaceuticals
    • 11.4.1 Ferring Pharmaceuticals: Collaborations and Agreement
    • 11.4.2 Ferring Pharmaceuticals: Drug Development Pipeline, 2019
    • 11.4.3 Ferring Pharmaceuticals: Key Pipeline Products, 2019
  • 11.5 AOBiome Therapeutics
    • 11.5.1 AOBiome Therapeutics: Collaborations and Agreement
    • 11.5.2 AOBiome Therapeutics: Drug Development Pipeline, 2019
    • 10.5.3. AOBiome Therapeutics: Key Pipeline Products, 2019
  • 11.6 Osel Inc.
    • 11.6.1 Osel Inc: Product Development Activities
    • 11.6.2 Osel Inc: Drug Development Pipeline, 2019
    • 11.6.3 Osel Inc: Key Pipeline Products, 2019
  • 11.7 Immuron Ltd
    • 11.7.1 Immuron: Collaboration and Agreement
    • 11.7.2 Immuron: Drug Development Pipeline, 2019
    • 11.7.3 Immuron: Key Pipeline Products, 2019
  • 11.8 Ritter Pharmaceuticals, Inc.
    • 11.8.1 Ritter Pharmaceuticals: Collaboration and Agreement
    • 11.8.2 Ritter Pharmaceuticals: Drug Development Pipeline, 2019
    • 11.8.3 Ritter Pharmaceuticals: Key Pipeline Products, 2019
  • 11.9 Intrexon Corporation
    • 11.9.1 Intrexon: Collaboration and Agreement
    • 11.9.2 Intrexon: Drug Development Pipeline, 2019
    • 11.9.3 Intrexon: Key Pipeline Products, 2019
  • 11.10 Synlogic
    • 11.10.1 Synlogic: Collaborations and Agreement
    • 11.10.2 Synlogic: Drug Development Pipeline, 2019
    • 11.10.3 Synlogic: Key Pipeline Products, 2019
  • 11.11 C3J Therapeutics
    • 11.11.1 C3J Therapeutics: Product Development Activities
    • 11.11.2 C3J Therapeutics: Drug Development Pipeline, 2019
    • 11.11.3 C3J Therapeutics: Key Pipeline Products, 2019
  • 11.12 Finch Therapeutics/Crestovo
    • 11.12.1 Finch/Crestovo: Collaboration and Agreement
    • 11.12.2 Finch/Crestovo: Drug Development Pipeline, 2019
    • 11.12.3 Finch/Crestovo: Key Pipeline Products, 2019
  • 11.13 MaaT Pharma
    • 11.13.1 MaaT Pharma: Collaboration and Agreement
    • 11.13.2 MaaT Pharma: Drug Development Pipeline, 2019
  • 11.14 IGEN BIOTECH GROUP
    • 11.14.1 IGEN BIOTECH: Product Development Activities
    • 11.14.2 IGEN BIOTECH: Key Pipeline Products
  • 11.15 MatriSys Biosystem
    • 11.15.1 MatriSys Biosystem: Product Development Activities
    • 11.15.2 MatriSys Biosystem: Drug Development Pipeline, 2019
    • 11.15.3 MatriSys Biosystem: Key Pipeline Products, 2019
  • 11.16 Second Genome
    • 11.16.1 Second Genome: Collaboration and Agreement
    • 11.16.2 Second Genome: Drug Development Pipeline, 2019
    • 11.16.3 Second Genome: Key Pipeline Products, 2019
  • 11.17 Microbiome Therapeutics LLC
    • 11.17.1 Microbiome Therapeutics: Product Development Activities
    • 11.17.2 Microbiome Therapeutics: Drug Development Pipeline, 2019
    • 11.17.3 Microbiome Therapeutics: Key Pipeline Products, 2019
  • 11.18 Caelus Health
    • 11.18.1 Caelus Health: Collaboration and Agreement
    • 11.18.2 Caelus Health: Drug Development Pipeline, 2019
    • 11.18.3 Caelus Health: Key Pipeline Products, 2019
  • 11.19 Enterome Bioscience
    • 11.19.1 Enterome Bioscience: Drug Development Pipeline, 2019
    • 11.19.2 Enterome Bioscience: Collaboration and Agreement
    • 11.19.3 Enterome Bioscience: Key Pipeline Products, 2019
  • 11.20 Vedanta Biosciences
    • 11.20.1 Vedanta Biosciences: Collaboration and Agreement
    • 11.20.2 Vedanta Biosciences: Drug Development Pipeline, 2019
    • 11.20.3 Vedanta Biosciences: Key Pipeline Products, 2019
  • 11.21 Symberix
    • 11.21.1 Symberix: Collaboration and Agreement
    • 11.21.2 Symberix: Drug Development Pipeline, 2019
    • 11.21.3 Symberix: Key Pipeline Products, 2019
  • 11.22 Quorum Innovations
    • 11.22.1 Quorum Innovations: Recent News
    • 11.22.2 Quorum Innovations: Drug Development Pipeline, 2019
    • 11.22.3 Quorum Innovations: Key Pipeline Products, 2019
  • 11.23 Assembly Biosciences
    • 11.23.1 Assembly Biosciences: Collaboration and Aggreement
    • 11.23.2 Assembly Biosciences: Drug Development Pipeline,2019
    • 11.23.3 Assembly Biosciences: Key Pipeline Products, 2019
  • 11.24 Evelo Biosciences, Inc.
    • 11.24.1 Evelo Biosciences, Inc.: Collaboration & Agreement
    • 11.24.2 Evelo Biosciences, Inc.: Drug Development Pipeline, 2019
    • 11.24.3 Evelo Biosciences, Inc.: Key Pipeline Products, 2019
  • 11.25 LOCUS BIOSCIENCES, INC.
    • 11.25.1 LOCUS BIOSCIENCES, INC.: Collabration & Agreement
    • 11.25.2 LOCUS BIOSCIENCES, INC.: Drug Development Pipeline, 2019
    • 11.25.3 LOCUS BIOSCIENCES, INC.: Key Pipeline Products, 2019
  • 11.26 ImmuneBiotech
    • 11.26.1 ImmuneBiotech: Collaboration & Agreement
    • 11.26.2 ImmuneBiotech: Drug Development Pipeline, 2019
    • 11.26.3 ImmuneBiotech: Key Pipeline Products, 2019
  • 11.27 LNC Therapeutics
    • 11.27.1 LNC Therapeutics: Collaboration & Agreement
    • 11.27.2 LNC Therapeutics: Drug Development Pipeline, 2019
    • 11.27.3 LNC Therapeutics: Key Pipeline Products, 2019
  • 11.28 BiomX
    • 11.28.1 BiomX: Collaboration & Agreement
    • 11.28.2 BiomX: Drug Development Pipeline, 2019
    • 11.28.3 BiomX: Key Pipeline Products, 2019
  • 11.29 Symbiotix Biotherapies, Inc.
    • 11.29.1 Symbiotix Biotherapies, Inc.: Collaboration & Agreement
    • 11.29.2 Symbiotix Biotherapies, Inc.: Drug Development Pipeline, 2019
    • 11.29.3 Symbiotix Biotherapies, Inc.: Key Pipeline Products, 2019
  • 11.30 LEADING BIOSCIENCES INC.
    • 11.30.1 LEADING BIOSCIENCES INC.: Drug Development Pipeline, 2019
    • 11.30.2 LEADING BIOSCIENCES INC.: Key Pipeline Products, 2019
  • 11.31 Azitra
    • 11.31.1 Azitra: Recent News
    • 11.31.2 Azitra: Drug Development Pipeline, 2019
    • 11.31.3 Azitra: Key Pipeline Products, 2019
  • 11.32 Rebiotix Inc.
    • 11.32.1 Rebiotix Inc.: Recent News
    • 11.32.2 Rebiotix Inc.: Drug Development Pipeline, 2019
    • 11.32.3 Rebiotix Inc.: Key Pipeline Products, 2019

12. Gastrointestinal Disorders: Key Products, 2019

  • 12.1 RBX2600 & RBX7455: Ferring Pharmaceuticals
  • 12.2 SER-109, SER287 & SER-262: Seres Therapeutics
  • 12.3 Ribaxamase & SYN-010: Synthetic Biologics
  • 12.4 IMM-529: Immuron
  • 12.5 SGM-1019: Second Genome
  • 12.6 Blautix, Thetanix & Rosburix: 4D Pharma
  • 12.7 EB8018: Enterome Bioscience

13. Metabolic Disorders: Key Products, 2019

  • 13.1 RP-G28: Ritter Pharmaceuticals
  • 13.2 IMM-124E: Immuron
  • 13.3 CP-001: Caelus Health
  • 13.4 NM504 & NM505: Microbiome Therapeutics
  • 13.5 SYNB1020: Synlogic

14. Infectious Diseases: Key Products, 2019

  • 14.1 LACTIN-V: Osel
  • 14.2 AOB-201: AOBiome Therapeutics
  • 14.3 MaaT001: MaaT Pharma
  • 14.4 CBM588: Osel Inc.

15. Dermatological Disorders: Key Products, 2019

  • 15.1 AOB101, AOB102 & AOB103: AOBiome Therapeutics
  • 15.2 MSB-01 & MSB-03: MatriSys Biosystem

16. Other Disorders: Key Products, 2019

  • 16.1 AG013: Intrexon
  • 16.2 AOB202 & AOB 203: AOBiome Therapeutics
  • 16.3 C16G2: C3J Therapeutics
  • 16.4 Microbiome Modulators: IGEN BIOTECH

17. Qualitative Analysis of the Human Microbiome Therapeutics, 2020-2030

  • 17.1 Market Factors Influencing Human Microbiome Therapeutics Market
  • 17.2 SWOT Analysis of the Global Human Microbiome Therapeutics Market, 2020-2030
    • 17.2.1 Strengths
      • 17.2.1.1 Novel & Efficient Therapies
      • 17.2.1.2 A Healthy R&D Pipeline
      • 17.2.1.3 Collaboration Among Key Industry Players
    • 17.2.2 Weaknesses
      • 17.2.2.1 Market Competition
      • 17.2.2.2 Consumer Perception
      • 17.2.2.3 Ethical Issues
      • 17.2.2.4 R&D Capabilities
      • 17.2.2.5 Knowledge Gaps
    • 17.2.3 Opportunities
      • 17.2.3.1 Growing Patient Pool
      • 17.2.3.2 Unmet Clinical Needs in Several Disease Areas
      • 17.2.3.3 Label Expansion
      • 17.2.3.4 Economic Growth in Emerging Market Provide Opportunity for Expansion
    • 17.2.4 Threats
      • 17.2.4.1 Capital Intensive Research
      • 17.2.4.2 Regulatory Approval
      • 17.2.4.3 Price
      • 17.2.4.4 Intellectual Property

18. Conclusions

  • 18.1 Overview of Current Market Conditions and Market Forecast, 2020-2030
  • 18.2 Leading Sectors in Human Microbiome Therapeutics in 2020
  • 18.3 Leading Regions in the Human Microbiome Therapeutics Market in 2020
  • 18.4 What Does the Future Hold for Microbiome Therapeutics?

Appendices

  • Glossary
  • Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Table

  • Table 4.1 Skin Disease and Related Microbiota
  • Table 5.1 Clinical Trial Phases
  • Table 6.1 Global Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2020
  • Table 6.2 Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Table 6.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Sector
  • Table 6.4 Global Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2020, 2024, 2030
  • Table 7.1 Global Human Microbiome Therapeutics Market for Gastrointestinal Disorders: Market Forecast ($m, AGR% and CAGR%), 2020-2030
  • Table 7.2 Global Human Microbiome Therapeutics Market for Infectious Diseases: Market
  • Forecast ($m, AGR% and CAGR%), 2020-2030
  • Table 7.3 Global Human Microbiome Therapeutics Market for Metabolic Diseases: Market
  • Forecast ($m, AGR% and CAGR%), 2020-2030
  • Table 7.4 Global Human Microbiome Therapeutics Market for Dermatological Conditions:
  • Market Forecast ($m, AGR% and CAGR%), 2020-2030
  • Table 7.5 Global Human Microbiome Therapeutics Market for Other Disorders: Market
  • Forecast ($m, AGR% and CAGR%), 2020-2030
  • Table 9.1 Global Human Microbiome Therapeutics Market: Market Size ($m) and Market Share (%) by Region, 2021
  • Table 9.2 Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2020-2030
  • Table 9.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region
  • Table 9.4 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2021, 2024, and 2030
  • Table 9.5 The US Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
  • Table 9.6 US Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
  • Table 9.7 The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Table 9.8 The United States Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
  • Table 9.9 EU5 Human Microbiome Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2020-2030
  • Table 9.10 EU5 Human Microbiome Drugs Market: Revenue ($m), and Market Share (%) by Country, 2021
  • Table 9.11 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), by Country, 2020-2030
  • Table 9.12 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021, 2024, 2030
  • Table 9.13 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Table 9.14 EU5 Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
  • Table 9.15 German Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2021-2030
  • Table 9.16 German Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
  • Table 9.17 German Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Table 9.18 German Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
  • Table 9.19 The French Human Microbiome Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
  • Table 9.20 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
  • Table 9.21 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Table 9.22 French Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
  • Table 9.23 The UK Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
  • Table 9.24 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
  • Table 9.25 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Table 9.26 UK Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
  • Table 9.27 Italian Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
  • Table 9.28 Italian Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
  • Table 9.29 Italian Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Table 9.30 Italian Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
  • Table 9.31 Spanish Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
  • Table 9.32 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
  • Table 9.33 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Table 9.34 Spanish Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
  • Table 9.35 APAC Human Microbiome Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2020-2030
  • Table 9.36 EU5 Human Microbiome Drugs Market: Revenue ($m), and Market Share (%) by Country, 2021
  • Table 9.37 APAC Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), by Country, 2020-2030
  • Table 9.38 APAC Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021, 2024, 2030
  • Table 9.39 APAC Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Table 9.40 APAC Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
  • Table 9.41 Japanese Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
  • Table 9.42 Japanese Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
  • Table 9.43 Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Table 9.44 Japan Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
  • Table 9.45 The Rest of the World Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
  • Table 9.46 Rest of the World Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
  • Table 10.1 Deals Human Health Therapeutics, 2017
  • Table 11.1 Pipeline Therapeutics by Companies
  • Table 11.2 4D Pharma: Company Overview, 2019
  • Table 11.3 4D Pharma: Key Pipeline Products, 2019
  • Table 11.4 Synthetic Biologics: Company Overview, 2019
  • Table 11.5 Synthetic Biologics: Key Pipeline Products, 2019
  • Table 11.6 Seres Therapeutics: Company Overview, 2019
  • Table 11.7 Clinical Trials Description
  • Table 11.8: Clinical Trials Description
  • Table 11.9 Clinical Trials Description
  • Table 11.10 Seres Therapeutics: Key Pipeline Products, 2019
  • Table 11.11 Ferring Pharmaceuticals: Company Overview, 2019
  • Table 11.12 Clinical Trials Description
  • Table 11.13 Clinical Trials Description
  • Table 11.14 Ferring Pharmaceuticals: Key Pipeline Products, 2019
  • Table 11.15 AOBiome, LLC: Company Overview, 2019
  • Table 11.16 Clinical Trials Description
  • Table 11.17 AOBiome Therapeutics: Key Pipeline Products, 2019
  • Table 11.18 Osel Inc: Company Overview, 2019
  • Table 11.19 Clinical Trials Description
  • Table 11.20 Osel Inc: Key Pipeline Products, 2019
  • Table 11.21 Immuron Ltd: Company Overview, 2019
  • Table 11.22 Clinical Trials Description
  • Table 11.23 Clinical Trials Description
  • Table 11.24 Key Pipeline Products, 2019
  • Table 11.25 Ritter Pharmaceuticals, Inc.: Company Overview, 2019
  • Table 11.26 Clinical Trials Description
  • Table 11.27 Ritter Pharmaceuticals: Key Pipeline Products, 2019
  • Table 11.28 Intrexon Corporation: Company Overview, 2019
  • Table 11.29 Clinical Trials Description
  • Table 11.30 Intrexon: Key Pipeline Products, 2019
  • Table 11.31 Synlogic: Company Overview, 2019
  • Table 11.32 Synlogic: Key Pipeline Products, 2019
  • Table 11.33 C3J Therapeutics: Company Overview, 2019
  • Table 11.34 Clinical Trials Description
  • Table 11.35 C3J Therapeutics: Key Pipeline Products, 2019
  • Table 11.36 Finch Therapeutics: Company Overview, 2019
  • Table 11.37 Clinical Trials Description
  • Table 11.38 Finch/Crestovo: Key Pipeline Products, 2019
  • Table 11.39 MaaT Pharma: Company Overview, 2019
  • Table 11.40 Clinical Trials Description
  • Table 11.41 IGEN BIOTECH GROUP: Company Overview, 2019
  • Table 11.42 IGEN BIOTECH: Key Pipeline Products
  • Table 11.43 MatriSys Biosystem: Company Overview, 2019
  • Table 11.44 MatriSys Biosystem: Key Pipeline Products, 2019
  • Table 11.45 Second Genome: Company Overview, 2019
  • Table 11.46 Second Genome: Key Pipeline Products, 2019
  • Table 11.47 Microbiome Therapeutics: Company Overview, 2019
  • Table 11.48 Clinical Trials Description
  • Table 11.49 Microbiome Therapeutics: Key Pipeline Products, 2019
  • Table 11.50 Caelus Health: Company Overview, 2019
  • Table 11.51 Key Pipeline Products, 2019
  • Table 11.52 Enterome Bioscience: Company Overview, 2019
  • Table 11.53 Clinical Trials Description
  • Table 11.54 Enterome Bioscience: Key Pipeline Products, 2019
  • Table 11.55 Vedanta Biosciences: Company Overview, 2019
  • Table 11.56 Vedanta Biosciences: Key Pipeline Products, 2019
  • Table 11.57 Symberix: Company Overview, 2019
  • Table 11.58 Key Pipeline Products, 2019
  • Table 11.59 Quorum Innovations: Company Overview, 2019
  • Table 11.60 Key Pipeline Products, 2019
  • Table 11.61 Assembly Biosciences: Company Overview, 2019
  • Table 11.62 Key Pipeline Products, 2019
  • Table 11.63 Evelo Biosciences, Inc.: Company Overview, 2019
  • Table 11.64 Key Pipeline Products, 2019
  • Table 11.65 LOCUS BIOSCIENCES, INC.: Company Overview, 2019
  • Table 11.66 Key Pipeline Products, 2019
  • Table 11.67 ImmuneBiotech: Company Overview, 2019
  • Table 11.68 Key Pipeline Products, 2019
  • Table 11.69 LNC Therapeutics: Company Overview, 2019
  • Table 11.70 Key Pipeline Products, 2019
  • Table 11.71 BiomX: Company Overview, 2019
  • Table 11.72 Key Pipeline Products, 2019
  • Table 11.73 Symbiotix Biotherapies, Inc.: Company Overview, 2019
  • Table 11.74 Key Pipeline Products, 2019
  • Table 11.75 LEADING BIOSCIENCES INC.: Company Overview, 2019
  • Table 11.76 Key Pipeline Products, 2019
  • Table 11.76 Azitra: Company Overview, 2019
  • Table 11.76 Key Pipeline Products, 2019
  • Table 11.77 Rebiotix Inc.: Company Overview, 2019
  • Table 11.78 Key Pipeline Products, 2019
  • Table 12.1 Gastrointestinal Disorders Drugs Pipeline: Key Drugs, 2019
  • Table 13.1 Metabolic Disorders Drugs Pipeline, 2019
  • Table 14.1 Infectious Disease Drugs Pipeline: Key Products, 2019
  • Table 15.1 Dermatological Disorders Drugs Pipeline: Key Products, 2019
  • Table 16.1 Other Disorders Drugs Pipeline: Key Products, 2019
  • Table 17.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2017-2028
  • Table 18.1 Global Human Microbiome Therapeutics: Market Forecast ($m, CAGR%), 2020, 2024 and 2030
  • Table 18.2 The Global Human Microbiome Therapeutics Market: Market Forecast ($m) by Region, 2020, 2024, 2030

List of Figure

  • Figure 1.1 Global Human Microbiome Therapeutics Market: Market Sectors
  • Figure 2.1 Role of Human Microbiota in Various Diseases
  • Figure 6.1 Global Human Microbiome Therapeutics Market: Revenue ($m) by Sector, 2020
  • Figure 6.2 Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2020-2030
  • Figure 6.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Sector, 2024-2030
  • Figure 6.4 Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2020
  • Figure 6.5 Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 6.6 Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
  • Figure 7.1 Global Human Microbiome Therapeutics Market for Gastrointestinal Disorders: Market Forecast ($m), 2020-2030
  • Figure 7.2 Global Human Microbiome Therapeutics Market for Infectious Diseases: Market Forecast ($m), 2020-2030
  • Figure 7.3 Global Human Microbiome Therapeutics Market for Metabolic Diseases: Market Forecast ($m), 2020-2030
  • Figure 7.4 Global Human Microbiome Therapeutics Market for Dermatological Conditions: Market Forecast ($m), 2020-2030
  • Figure 7.5 Global Human Microbiome Therapeutics Market for Other Disorders: Market Forecast ($m), 2020-2030
  • Figure 9.1 Global Human Microbiome Therapeutics Market: Market Size ($m) by Region, 2021
  • Figure 9.2 US, EU, APAC and ROW Human Microbiome Therapeutics Market: Market Forecast ($m), 2020-2030
  • Figure 9.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region, 2021-2024
  • Figure 9.4 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region, 2024-2030
  • Figure 9.5 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region, 2021-2030
  • Figure 9.6 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2021
  • Figure 9.7 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2024
  • Figure 9.8 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2030
  • Figure 9.9 US Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2020-2030
  • Figure 9.10 The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Figure 9.11 The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
  • Figure 9.12 The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 9.13 The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
  • Figure 9.14 EU5 Human Microbiome Drugs Market: Revenue ($m) by Country, 2021
  • Figure 9.15 Germany, France, UK, Italy, and Spain Human Microbiome Drugs Market: Market Forecast ($m), 2020-2030
  • Figure 9.16 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021
  • Figure 9.17 The EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2024
  • Figure 9.18 The EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2030
  • Figure 9.19 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Figure 9.20 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
  • Figure 9.21 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 9.22 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
  • Figure 9.23 German Human Microbiome Therapeutics Market: Market Forecast ($m), 2020-2030
  • Figure 9.24 German Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Figure 9.25 German Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
  • Figure 9.26 German Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 9.27 German Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
  • Figure 9.28 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2020-2030
  • Figure 9.29 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Figure 9.30 French Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
  • Figure 9.31 French Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 9.32 French Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
  • Figure 9.33 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2020-2030
  • Figure 9.34 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Figure 9.35 UK Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
  • Figure 9.36 UK Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 9.37 UK Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
  • Figure 9.38 Italian Human Therapeutics Market: Market Forecast ($m, AGR%), 2020-2030
  • Figure 9.39 Italian Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Figure 9.40 Italian Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
  • Figure 9.41 Italian Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 9.42 Italian Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
  • Figure 9.43 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2020-2030
  • Figure 9.44 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Figure 9.45 Spanish Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
  • Figure 9.46 Spanish Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 9.47 Spanish Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
  • Figure 9.48 APAC Human Microbiome Drugs Market: Revenue ($m) by Country, 2021
  • Figure 9.49 Japan, China, India, Australia, Korea and Others Human Microbiome Drugs Market: Market Forecast ($m), 2020-2030
  • Figure 9.50 APAC Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021
  • Figure 9.51 APAC Human Microbiome Therapeutics Market: Market Share (%) by Country, 2024
  • Figure 9.52 APAC Human Microbiome Therapeutics Market: Market Share (%) by Country, 2030
  • Figure 9.53 APAC Human Microbiome Therapeutics Market: Market Forecast ($m) by Sector, 2020-2030
  • Figure 9.54 APAC Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
  • Figure 9.55 APAC Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 9.56 APAC Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
  • Figure 9.57 Japanese Human Microbiome Therapeutics Market: Market Forecast ($m), 2020-2030
  • Figure 9.58 Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
  • Figure 9.59 Japan Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 9.60 Japan Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
  • Figure 9.32 Rest of the World Human Microbiome Therapeutics Market: Market Forecast ($m), 2020-2030
  • Figure 11.1 Enterome Bioscience
  • Figure 11.2 Evelo Biosciences, Inc.
  • Figure 18.1 Global Human Microbiome Therapeutics: Market Forecast ($m), 2020- 2030
  • Figure 18.2 The Global Human Microbiome Therapeutics Market: Market Forecast ($m) by Region, 2020-2030

List of Companies Mentioned in the Report:

  • 4D Pharma
  • 4D Pharma Cork Limited
  • 4D Pharma Leon
  • AbbVie S.à.r.l.
  • Accinov
  • ActoGeniX
  • Aju IB Investment
  • Ally Bridge Group
  • Amrita Therapeutics
  • AOBiome, LLC
  • AquaBounty Technologies
  • Arctic Aurora Life Science
  • Aspire Capital Fund
  • Assembly Biosciences
  • Azitra
  • BaseClear
  • BIOASTER
  • Biological & Popular Culture, Inc.
  • BiomX
  • Bio-Technology General
  • Blue Turtle Bio
  • Bristol-Myers Squibb
  • BYTC Corp
  • C3J Therapeutics
  • Caelus Health
  • Cd4 Biosciences, Inc.
  • Cedars-Sinai Medical Centre
  • Chengdu Sen Nuo Wei Biotechnology Co., Ltd
  • CLI Ventures
  • Codexis Laboratories Hungary Kft
  • CoreBiome
  • Crestovo
  • CRS Bio, Inc
  • DayTwo
  • Digitalis Ventures
  • Effective Pharmaceuticals, Inc.
  • Enterome Bioscience
  • Enterome SA
  • EnviroFlight, LLC
  • Epibiome
  • Epitope Pharmaceuticals, Inc.
  • Evelo Biosciences
  • Evolve BioSystems
  • Ferring Pharmaceuticals
  • Ferring Sas
  • Finch Therapeutics Group, Inc.
  • Finch Therapeutics
  • Genomatix Ltd.
  • Genten Therapeutics, Inc.
  • GenVec, Inc.
  • Global Bioscience Company
  • GT Biologics Limited
  • Hartlab LLC
  • Harvest Capital Strategies, LLC
  • HealthMine, Inc
  • IBBL
  • iCarbonX
  • Igen Biotech Group
  • ImmuneBiotech AB
  • Immuron, Ltd.
  • INC Research
  • INRA transfer
  • Intrexon
  • Intrexon Actobiotics N.V.
  • Intrexon Corporation
  • Intrexon Crop Protection
  • Intrexon Energy Partners II, LLC
  • Intrexon Energy Partners, LLC
  • Intrexon T1D Partners
  • Janssen Biotech
  • Johnson & Johnson
  • Kallyope
  • Kolu Pohaku Management, LLC
  • Kolu Pohaku Technologies
  • Leading Biosciences
  • LNC Therapeutics
  • Lundbeckfond Ventures
  • MaaT Pharma SA
  • MatriSys Bioscience
  • MatriSys Biosystem
  • Mayo Clinic
  • Medistem, Inc.
  • Medpace
  • Merck & Co., Inc.
  • Microbiome Therapeutics, LLC
  • Microbiomics Limited
  • Mirna Therapeutics
  • Nestle Health Science
  • Nitrocell
  • NIZO
  • Nubiyota
  • NuMe Health LLC
  • Okanagan Specialty Fruits Inc.
  • Omnes Capital
  • OpenBiome
  • OptiBiotix Health plc
  • OrbiMed HealthCare Fund Management
  • Osel, Inc.
  • OvaXon, LLC
  • Oxitec
  • Perceptive Advisors
  • Pfizer Venture Investments
  • Pharm-Olam International
  • Pipex Therapeutics, Inc
  • Precigen, Inc.
  • Prev AbR LLC
  • ProDigest
  • PureTech Health
  • Putney Drug Corp
  • Pylum Biosciences
  • Quorum Innovations
  • Rebiotix, Inc
  • Ritter Natural Sciences, LLC
  • Ritter Pharmaceuticals
  • Roche Venture Fund
  • Rock Springs Capital
  • S & I Ophthalmic
  • S-Biomedic
  • Second Genome
  • Seres Therapeutics
  • Seventure Partners
  • Shire
  • Solovax, Inc
  • SR One Venture Partners
  • Symberix
  • Symbiotic Health
  • Symbiotix Biotherapies
  • Synlogic, Inc.
  • Synthetic Biologics, Inc.
  • Synthetic Biomics Inc.
  • Synthetic Genomics, Inc.
  • Takeda
  • TargEDys
  • Tech Coast Angels (TCA)
  • The Microbiota Company Limited
  • Trans Ova Genetics LC
  • Tucana Health Limited
  • Vedanta Biosciences Inc.
  • Veristat
  • Vertex Pharmaceuticals Inc.
  • Whole Biome
  • Xycrobe Therapeutics

List of Organizations Mentioned in the Report:

  • Alimentary Pharmabiotic Centre
  • American Academy of Dermatology
  • APC Microbiome Institute
  • Central Drugs Standard Control Organisation (CDSCO)
  • French National Institute for Agricultural Research
  • Hadasit Medical Research Services & Development Ltd
  • Hadassah Medical Center
  • Health Canada
  • Institut National de la Recherche Agronomique
  • Integrium
  • John Theurer Cancer Center of Hackensack Meridian Health
  • King's College London
  • La Trobe University
  • Lawrence Berkeley National Laboratory
  • Leiden University Medical Center
  • Mayo clinic
  • Medicines Control Council (MCC)
  • Medical University of Graz
  • Memorial Sloan Kettering Cancer Center
  • Ministry of Health, Labour and Welfare (MHLW)
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • Microbiome Institute at University College Cork
  • Monash University
  • Murdoch Children Research Institute
  • National Institute of Allergy and Infectious Diseases
  • NYU Langone Health
  • Orange Country Research Center
  • Pan American Health Organization (PAHO)
  • Roswell Park Comprehensive Cancer Center
  • Ruprecht-Karls-University Heidelberg
  • Saudi Food and Drug Authority (SFDA)
  • St. Joseph's Hamilton
  • Stanford Cancer Institute
  • Therapeutic Goods Administration (TGA)
  • The Endocrine Society
  • The Parker Institute for Cancer Immunotherapy
  • University of British Columbia
  • University of California
  • University of Melbourne
  • University of Minnesota
  • University of Nebraska
  • University of Pennsylvania
  • University of South Alabama (USA) Mitchell Cancer Institute
  • University of Texas at Austin
  • University of Texas MD Anderson Cancer Center
  • University of Tokyo
  • USA Mitchell Cancer Center
  • World Health Organization (WHO)
  • World Intellectual Property Organization WIPO
  • World Trade Organization (WTO)